Publications by authors named "Jonathan M Edelman"

Claim this Profile
S
Safety, immunogenicity and efficacy of the self-amplifying mRNA ARCT-154 COVID-19 vaccine: pooled phase 1, 2, 3a and 3b randomized, controlled trials.
Nhân Thị Hồ, Steven G Hughes, Van Thanh Ta, Lân Trọng Phan, Quyết Đỗ, Jonathan M Edelman

Nat Commun· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of a Cell-Culture-Derived Quadrivalent Influenza Vaccine in Children.
Terence Nolan, Alexandre C Fortanier, Brett Leav, Airi Põder, Lulu C Bravo, Jonathan M Edelman

N Engl J Med· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative disease progression model of α-1 proteinase inhibitor therapy on computed tomography lung density in patients with α-1 antitrypsin deficiency.
Michael A Tortorici, James A Rogers, Oliver Vit, Martin Bexon, Robert A Sandhaus, Jonathan M Edelman

Br J Clin Pharmacol· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Minimum clinically important difference analysis confirms the efficacy of IgPro10 in CIDP: the PRIMA trial.
Ingemar S J Merkies, John-Philip Lawo, Jonathan M Edelman, Jan L De Bleecker, Claudia Sommer

J Peripher Nerv Syst· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE).
Noel G McElvaney, Jonathan Burdon, Mark Holmes, Allan Glanville, Peter A B Wark, Jonathan M Edelman

Lancet Respir Med· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Effect of Alpha-1 Proteinase Inhibitor on Biomarkers of Elastin Degradation in Alpha-1 Antitrypsin Deficiency: An Analysis of the RAPID/RAPID Extension Trials.
Shuren Ma, Yong Y Lin, Jerome O Cantor, Kenneth R Chapman, Robert A Sandhaus, Jonathan M Edelman

Chronic Obstr Pulm Dis· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial.
Kenneth R Chapman, Jonathan G W Burdon, Eeva Piitulainen, Robert A Sandhaus, Niels Seersholm, Jonathan M Edelman

Lancet· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Trial Design for Alpha-1 Antitrypsin Deficiency: A Model for Rare Diseases.
Adam Wanner, Stephen C Groft, J Russell Teagarden, Jeffrey Krischer, Barry R Davis, Jonathan M Edelman

Chronic Obstr Pulm Dis· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serial assessment of the electrocardiographic strain pattern for prediction of new-onset heart failure during antihypertensive treatment: the LIFE study.
Peter M Okin, Lasse Oikarinen, Matti Viitasalo, Lauri Toivonen, Sverre E Kjeldsen, Jonathan M Edelman

Eur J Heart Fail· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy.
Peter M Okin, Sverre E Kjeldsen, Stevo Julius, Darcy A Hille, Björn Dahlöf, Jonathan M Edelman

Eur Heart J· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Back to School asthma study: the effect of montelukast on asthma burden when initiated prophylactically at the start of the school year.
Kevin B Weiss, James E Gern, Neil W Johnston, Malcolm R Sears, Craig A Jones, Jonathan M Edelman

Ann Allergy Asthma Immunol· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Greater regression of electrocardiographic left ventricular hypertrophy during hydrochlorothiazide therapy in hypertensive patients.
Peter M Okin, Darcy A Hille, Sverre E Kjeldsen, Lars H Lindholm, Jonathan M Edelman

Am J Hypertens· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention for Endpoint reduction in hypertension study.
Sverre E Kjeldsen, Richard B Devereux, Darcy A Hille, Paulette A Lyle, Björn Dahlöf, Jonathan M Edelman

Blood Press· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of ACE insertion/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the LIFE study.
Børge G Nordestgaard, Kimmo Kontula, Marianne Benn, Björn Dahlöf, Ulf de Faire, Jonathan M Edelman

Pharmacogenet Genomics· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence of heart failure in relation to QRS duration during antihypertensive therapy: the LIFE study.
Peter M Okin, Richard B Devereux, Sverre E Kjeldsen, Jonathan M Edelman, Björn Dahlöf

J Hypertens· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE).
Peter M Okin, Lasse Oikarinen, Matti Viitasalo, Lauri Toivonen, Sverre E Kjeldsen, Jonathan M Edelman

Circulation· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study.
Peter M Okin, Kristian Wachtell, Sverre E Kjeldsen, Stevo Julius, Lars H Lindholm, Jonathan M Edelman

Circ Arrhythm Electrophysiol· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ADVANTAGE: science first, marketing second.
Jonathan M Edelman

Ann Intern Med· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ADVANTAGE: Merck does say "no".
Jonathan M Edelman

Ann Intern Med· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gender differences in regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy.
Peter M Okin, Eva Gerdts, Sverre E Kjeldsen, Stevo Julius, Jonathan M Edelman

Hypertension· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients.
Peter M Okin, Richard B Devereux, Katherine E Harris, Sverker Jern, Sverre E Kjeldsen, Jonathan M Edelman

Ann Intern Med· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atenolol as a comparator in outcome trials in hypertension: a correct choice in the past, but not for the future?
Björn Dahlöf, Richard B Devereux, Sverre E Kjeldsen, Paulette A Lyle, Zhongxin Zhang, Jonathan M Edelman

Blood Press· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adherence with montelukast or fluticasone in a long-term clinical trial: results from the mild asthma montelukast versus inhaled corticosteroid trial.
Cynthia Rand, Andrew Bilderback, Kathleen Schiller, Jonathan M Edelman, Carolyn M Hustad

J Allergy Clin Immunol· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension.
Peter M Okin, Kristian Wachtell, Richard B Devereux, Katherine E Harris, Sverker Jern, Jonathan M Edelman

JAMA· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.
Peter M Okin, Richard B Devereux, Eva Gerdts, Steven M Snapinn, Katherine E Harris, Jonathan M Edelman

Circulation· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis